Merck Research Labs president presents at Citi 2016 conference
Merck Research Laboratories President Dr. Roger Perlmutter participated in the Citi 2016 Global Healthcare Conference Wednesday in New York. Read More »
Merck Research Laboratories President Dr. Roger Perlmutter participated in the Citi 2016 Global Healthcare Conference Wednesday in New York. Read More »
Novo Nordisk's Changing Diabetes in Children program has received a four-year extension to provide access to diabetes care and free insulin to children in developing countries who have Type 1 diabetes. Read More »
Merck has released new data involving KEYTRUDA, Merck’s anti-PD-1 therapy designed for the treatment of a number of blood cancers, and its investigational use. Read More »
Merck KGaA's businesses in Massachusetts have been ranked among the “Top Places to Work” by The Boston Globe. Read More »
Merck has received the R&D 100 Award from R&D magazine. Read More »
Kedrion Biopharma and Kamada's Biologics License Application for human anti-rabies immunoglobulin therapy has been accepted for review by the U.S. Food and Drug Administration. Read More »
Merck KGaA will present the data on its investigational drug for the treatment of systemic lupus erythematosus ataciept at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting. Read More »
A licensing agreement with Norgine B.V. will give Valeant Pharmaceuticals the rights to the development and commercialization of NER1006 Powder for Oral Solution in the United States and Canada. Read More »
Valeant Pharmaceuticals and Progenics Pharmaceuticals have commercially released RELISTOR Tablets in the United States and it is now available for prescription. Read More »
The Food and Drug Administration has approved Allergan's RESTASIS MULTIDOSE, its bottled version of RESTASIS, both of which are free of preservatives. Read More »
Braeburn Pharmaceuticals and Camurus have extended their partnership and license agreement to include buprenorphine combination products. Read More »
Newron Pharmaceuticals, in association with its partners Zambon and US WorldMeds, has resubmitted the U.S. New Drug Application in September seeking a complete Class 2 response by the U.S. Food and Drug Administration for Xadago, also known by its generic name, safinamide. Read More »
Recent data from Allergan's range of irritable bowel syndrome treatments were the focus of two poster presentations at the American College of Gastroenterology Annual Scientific Meeting. Read More »
Allergan will continue its collaborative efforts with Dystonia Medical Research Foundation to support patients with dystonia by conducting a survey that will assess cervical dystonia awareness, its symptoms and options for treatment that will inspire education and the correct diagnosis of the condition, which can often be disabling. Read More »
The buprenorphine/naloxone CIII sublingual tablet ZUBSOLV from Orexo US has been approved by the U.S. Food and Drug Administration. Read More »
Braeburn Pharmaceuticals and Camurus have enrolled the first Phase 3 CAM2038 trial patients to assess the safety and effectiveness of CAM2038 in patients with lower back pain whose present course of treatment involves opioids. Read More »
Ajanta Pharma USA has made Omeprazole and Sodium Bicarbonate Powder for Oral Suspension available in the United States. Read More »
Allergan Inc. recently announced the acquisition of Akarna Therapeutics for an upfront payment of $50 million. Read More »
Allergen plc recently announced that NAMZARIC is now available through prescription in pharmacies across the United States. Read More »
Valeant Pharmaceuticals International has appointed of Paul S. Herendeen as the company’s new EVP of Finance. Read More »